Disclaimer: Due to limited expertise, errors are inevitable, and some information may not be the most up-to-date. Comments pointing out any inaccuracies are welcome. This article is only an introduction to medical and health-related drugs, not a recommendation of treatment plans (if involved); it does not constitute any investment advice.
Recently, the Phase I Clinical Trial Initiation Meeting for IBR733 Cell Injection, developed by Imbioray (Hangzhou) Biopharmaceutical Co., Ltd. to treat acute myeloid leukemia, was successfully held at the First Affiliated Hospital of Soochow University.
This trial is jointly led by Professor Depei Wu from the First Affiliated Hospital of Soochow University and Professor Weili Zhao from Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, in collaboration with renowned clinical research centers in China, including the First Affiliated Hospital of Zhejiang University School of Medicine, West China Hospital of Sichuan University, and Zhongda Hospital affiliated with Southeast University.
The launch meeting invited Professor Tang Xiaowen, the administrative deputy director of the Hematology Department of the First Affiliated Hospital of Soochow University, and the clinical research team from related departments, Dr. Mei Shuang, Vice President of R&D at Imbioray, the Imbioray clinical team, and the operations team from the CRO company TigerMed. The launch meeting was chaired by Professor Tang Xiaowen. The meeting introduced the implementation process and details of the Phase I clinical trial protocol for IBR733 cell injection in treating acute myeloid leukemia. Participants thoroughly discussed and analyzed the key points and challenges of this trial, proposing many practical suggestions and measures, laying a solid foundation for the high-quality execution of the trial.The successful launch of this kick-off meeting marks the official start of Imbioray's IBR733 Cell Injection for the treatment of acute myeloid leukemia in Phase I clinical trials, with participant recruitment now underway. Subsequently, Imbioray will work closely with various clinical centers and experts to advance this clinical trial with high quality and efficiency, anticipating fruitful clinical research outcomes that will benefit a wide range of patients with acute myeloid leukemia.About IBR733 Cell InjectionIBR733 Cell Injection is the world's first CD33 and CLL1 dual-target antibody-conjugated NK cell product approved for IND clinical research for acute myeloid leukemia indications. It uses imbioray's proprietary tumor antigen-targeting specific antibodies, CD33/CLL1, which are chemically covalently conjugated to NK cells via a linker. This off-the-shelf, universal NK cell product is non-viral vector and non-genetically modified, featuring extremely high safety and potent tumor cell-killing ability. IBR733 Cell Injection has already undergone multiple investigator-initiated clinical trials (IIT) in the early stages, achieving excellent results in both safety and efficacy. It is expected to bring new treatment options and survival hope to more patients with acute myeloid leukemia.Imbioray is a clinical-stage and venture capital-backed biopharmaceutical company primarily focused on the development of innovative drugs for immunotherapy in globally advanced cancer treatments, as well as immune-related diseases, chronic conditions, and CNS disorders. Dr. Zhenwei Miao, the founder of Imbioray, returned to China in 2016 to establish the company, setting the direction for developing off-the-shelf cell therapies based on NK cells. Imbioray has four internationally unique core technology platforms that accelerate its original innovations, along with advanced processes for large-scale in vitro closed-system cultivation of NK cells. Based on its proprietary antibody-conjugated NK cell platform technology, Imbioray has developed several off-the-shelf cell therapy products, including IBR854, IBR733, and IBR822. Currently, IBR854, the world’s first cell injection for advanced solid tumors, and IBR733, the world’s first cell injection for acute myeloid leukemia, have both entered Phase I clinical trials. IBR822, the third antibody-NK cell conjugate drug developed by Imbioray, recently completed its IND submission and has been accepted by the CDE.Source: imbioray Bio
